Enveric Biosciences IncNASDAQ ENVB Stock Report

Enveric Biosciences, Inc. develops cannabinoid medicines and combination therapies. The company is headquartered in Naples Florida, Florida and currently employs 23 full-time employees. The company went IPO on 2009-07-21. The firm is developing next-generation mental health and oncology treatments using a clinical discovery platform to enable psychedelic-derived molecules for the mind and synthetic cannabinoids for the body. The company is developing its product candidates that are focused on cannabinoids derived from non-hemp botanical sources, and synthetic materials containing no tetrahydrocannabinol (THC) in order to comply with United States federal regulations. Its product candidates include EV104, EVM-101, EVM-201, EVM-301, EV102 and EV101. EV104 includes cannabidiol (CBD) and celecoxib conjugate. EVM-101 is a first-generation psychedelic asset, which is a psilocybin oral formulation. EVM-201 is a second-generation psychedelic asset, which is a prodrug of psilocin. EVM-301 is a third-generation psychedelic. EV102 is a cannabinoid cream for topical skin application. EV101 is a cannabinoid plus chemotherapy combination therapy.